Skip to main content
. 2023 May 3;19(5):e1011323. doi: 10.1371/journal.ppat.1011323

Fig 6. Effect of Avasimibe on SARS-CoV-2-specific CD4+ T cells in acute infection.

Fig 6

(a-e) Human PBMC from donors with acute SARS-CoV-2 infection were stimulated with SARS-CoV-2 peptide pools (Spike and Membrane, Mem) and treated with Avasimibe (AVS) or DMSO for 8 days. SARS-CoV-2-specific cytokine production by CD4+ T cells was detected via flow cytometry. The cytokine production/CD154 expression in wells without peptide stimulation was subtracted to determine SARS-CoV-2-specific cytokine production/CD154 expression in summary data. Example plots and summary data for SARS-CoV-2 specific IFNγ (a), TNF (b), MIP1β (c) production and CD154 expression (d) by CD4+ T cells (n = 19). (e) Assessment of SARS-CoV-2-specific proliferation determined by CFSE dilution gated on IFNγ+ CD4+ T cells (Spike n = 10; Mem n = 11). Bars represent the mean of the data set. Doughnut charts indicate fraction of donors with response to AVS (red). Response defined as de novo or increased cytokine production/CD154 expression. P values determined by Wilcoxon matched-pairs signed rank test.